Cathie Wood Just Bought This Small Cap Stock Seven Days Straight: Should Investors Take Note?

Core Viewpoint - Cathie Wood's Ark Invest has been actively purchasing shares of GeneDx Holdings Corp, a small-cap diagnostic testing company, which may indicate potential investment interest as the company has shown strong financial performance and growth prospects [1][2]. Group 1: Ark Invest's Trading Activity - Ark Invest's ETFs have outperformed the S&P 500 in 2025, making their stock picks noteworthy for investors [2]. - Over the last seven trading days, ARKK purchased 79,059 shares and ARKG added 62,328 shares of GeneDx Holdings [3]. - The increased holdings in GeneDx Holdings come after the company reported strong quarterly financial results [3]. Group 2: GeneDx Holdings Financial Performance - GeneDx reported fourth-quarter revenue of $121 million, reflecting a 27% year-over-year increase, and has beaten analyst estimates for earnings per share for 10 consecutive quarters [4]. - For the full fiscal year, GeneDx's revenue reached $427.5 million, up 41% year-over-year, with exome and genome test results volume increasing by 30.5% [5]. - The company projects 2026 revenue between $540 million and $555 million, indicating a positive growth outlook [5]. Group 3: Expansion and Market Position - GeneDx is expanding into new markets, particularly in prenatal diagnostics, which could provide additional growth opportunities [6]. - The company is also seeing increased payer coverage, including Medicaid for exome and genome sequencing in new states, which may enhance its market position [6]. Group 4: Stock Performance - GeneDx stock is currently trading at $81.40, with a 52-week trading range of $55.17 to $170.87, and has experienced a year-to-date decline of 37.8% in 2026 [9].